Receptor for advanced glycation end products (RAGE) in vascular and inflammatory diseases

Nitin Mahajan, Veena Dhawan

Research output: Contribution to journalReview article

44 Scopus citations


Historically, the receptor for advanced glycation end products (RAGE) was thought to exclusively play an important role under hyperglycemic conditions. However, more and more evidence suggests that RAGE in fact is an inflammation perpetuating multi-ligand receptor and participates actively in various vascular and inflammatory diseases even in normoglycaemic conditions. Various ligands include advanced glycation end products (AGEs), S100 proteins and amphoterins etc. Besides full-length RAGE, numerous truncated forms of the receptor have also been described including the well-characterized soluble RAGE (sRAGE). sRAGE has an ability to act as a decoy to avoid interaction of RAGE with its pro-inflammatory ligands. Ligand engagement of RAGE activates multiple signaling pathways and also forms a positive feedback loop for its own enhanced expression. This review will discuss the role of multi-ligand receptor i.e. RAGE in context to various vascular diseases, which have a pathophysiologically important inflammatory component in normoglycaemic conditions.

Original languageEnglish
Pages (from-to)1788-1794
Number of pages7
JournalInternational Journal of Cardiology
Issue number3
StatePublished - Oct 3 2013
Externally publishedYes


  • Atherosclerosis
  • Inflammation
  • RAGE
  • sRAGE

Fingerprint Dive into the research topics of 'Receptor for advanced glycation end products (RAGE) in vascular and inflammatory diseases'. Together they form a unique fingerprint.

  • Cite this